SICK at a glance
IFRS figures for the SICK Group
| 2024 | 2023 | 2022 | 2021 | 2020 | |
Net sales (in millions of EUR) | 1,736.8 | 1,962.8 | 2,189.8 | 1,964 | 1,700.2 |
| EBIT (in millions of EUR) | 55.0 | 150.7 | 164.6 | 202.3 | 140.6 |
| Annual profit (in millions of EUR) | 237.3 | 134.4 | 119.5 | 147.8 | 101.1 |
| Cash flow (in millions of EUR) | 140.6 | 117.6 | 55.0 | 231.1 | 227.7 |
| Employees as at December 31 | 11,804 | 12,185 | 11,909 | 11,022 | 10,433 |
| R&D expenditure (in millions of euros) | 231.6 | 234.6 | 240.8 | 210.3 | 201.1 |
| Earnings per share (in EUR) | 9.05 | 5.12 | 4.56 | 5.64 | 3.86 |
Note: In the 2024 financial year, SICK agreed a strategic partnership with Endress+Hauser for process automation. For this reason, the accounting standard IFRS 5 must be applied for the 2024 financial year. This requires the comparative figures for the 2023 financial year to be adjusted and are therefore no longer comparable with previous years. The financial results for 2023 and subsequent years do not include the “Cleaner Industries” business unit, which will not be continued within SICK AG from 2025 as a result of the partnership.